Molecular analyses of peritoneal metastasis from colorectal cancer

Background: Despite a trend showing continued improvement in survival by combing targeted agents for colorectal cancer (CRC), the observed is limited. Moreover, clinically relevant benefits were not achieved peritoneal metastasis cases. The role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been questioned. This review aimed to provide an overview current status studies reporting on molecular knowledge from CRC (CRC-PM).Current Concepts: PRODIGE 7 study was performed assess specific contributions HIPEC benefit CRC-PM cases comparing CRS treatment alone with oxaliplatin-based HIPEC. However, this did reveal any improvement, oxaliplatin resistance suggested as main cause negative outcome. Hence, relative consensus subtype (CMS) 4 great interest.Discussion Conclusion: Recent treatments metastatic gradually moved precision medicine based individual biological information through high-throughput technology, such next-generation sequencing. In transcriptome study, identified almost homogeneous CMS4 classification, which known strong chemotherapy. These results suggest need clarify complex sub-signal transmission pathways derived or proteome CRC-PM. Finally, compare two studies, it necessary establish representative patient group consider standardized sample collection, treatment, analysis.